An interventional study of Tranexamic acid in Hip Fractures, sponsored by University Hospital for Surgical Diseases St. Naum Ohridsk i- Skopje. Recruiting at 1 site in North Macedonia. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by University Hospital for Surgical Diseases St. Naum Ohridsk i- Skopje · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing Tranexamic Acid in Hip Fractures — 2 open to participants now, 3 under way, none of them phase 3. Tranexamic Acid · Hip Fractures.
Among the 22 studies testing Tranexamic Acid in Hip Fractures, this one is the 10th largest by planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2026, is one of 6 with no phase, and was the 22nd registered.
843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.
Browse Hip Fractures studies →2 of the 22 studies testing Tranexamic Acid in Hip Fractures are open now, in 2 countries. Recruiting first, the newest first:
Biogipuzkoa Health Research Institute · Sites in Spain
Ages 65+
By country, each count listing its studies:
Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →
Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 86 across 534 interventional studies indexed under Hip Fractures.
Median enrollment 120 across the 21 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 22 has an industry lead sponsor. The 10 most frequent:
University Hospital for Surgical Diseases St. Naum Ohridsk i- Skopje is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
University Hospital for Surgical Diseases St. Naum Ohridsk i- Skopje has 1 study filed under Hip Fractures — fewer than ten, so there is no comparison to draw.
2 of the studies testing Tranexamic Acid in Hip Fractures that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07432737University Hospital for Surgical Diseases St. Naum Ohridsk i- SkopjeOne Versus Two Doses of Tranexamic Acid in Surgically Treated Extracapsular Hip Fractures | 2027-05 |
| NCT03063892Gregory M Georgiadis MDEffect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion | 2027-07-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies testing Tranexamic Acid in Hip Fractures, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn whether giving one dose or two doses of tranexamic acid can safely lower blood loss in older adults having surgery for certain hip fractures. The study includes adults aged 65 years or older who need surgery for pertrochanteric or subtrochanteric hip fractures.
The main questions the study aims to answer are:
Participants will:
This prospective, randomized,single-center clinical study is conducted at the University Clinic for Surgical Diseases "St. Naum Ohridski." Adults aged 65 years or older with pertrochanteric or subtrochanteric femoral fractures are eligible. All patients undergo surgery within 48 hours of admission, according to current recommendations for treatment of pertrochanteric and subtrochanteric fractures. Fractures are classified according to the AO/OTA system by at least two trauma surgeons; discrepancies are resolved by discussion.
Routine preoperative evaluation is performed according to institutional standards and may include patient history, physical examination, standard imaging (X-ray of the pelvis and affected hip, with additional CT scans if indicated), laboratory tests including complete blood count, biochemistry, and coagulation tests, as well as anesthesia assessment. Relevant comorbidities and chronic medications are recorded.
Eligible participants are randomly assigned to one of two treatment groups. One group receives a single prophylactic dose of tranexamic acid, while the other receives two doses according to the study protocol. All participants receive standard surgical and anesthetic care in accordance with institutional practice.
Surgical Procedure:
Surgery is performed under spinal or general anesthesia. Stable pertrochanteric fractures are treated with DHS or short intramedullary nail. Unstable pertrochanteric and subtrochanteric fractures are treated with intramedullary nailing. Reduction may be open or closed, with fluoroscopic guidance. Wound closure is standard; drain placement is at surgeon discretion.
Blood Loss Measurement:
Intraoperative visible blood loss (VBLop) is calculated as suction volume minus irrigation fluids plus blood in sponges, visually estimated.Total visible blood loss (VBL) is the sum of VBLop and drain output. Total blood loss (TBL) is calculated using standard formulas based on preoperative and postoperative hematocrit and red blood cell transfusions. Blood volume is calculated using standard formulas. Hidden blood loss (HBL) is calculated as total blood loss minus visible blood loss (TBL minus VBL).
Red blood cell transfusions are given if hemoglobin is less than 8 grams per deciliter or if symptomatic anemia occurs.
Postoperative Monitoring:
Laboratory tests (Hb, Hct, urea, creatinine, electrolytes) are measured 6 hours postoperatively, then daily up to day 3, or longer if clinically indicated.. Blood products administered per clinical indication. Early mobilization usually on post-op day 1-2. Intensive care unitstay and total hospitalization recorded.
All patients will receive antibiotic prophylaxis according to the institutional protocol. Thromboprophylaxis will be administered using a combined approach, including pharmacologic measures (enoxaparin or an oral anticoagulant if indicated) and mechanical measures (high-compression stockings until full mobilization). Adverse events and complications will be monitored and documented during hospitalization and up to 90 days postoperatively. Routine postoperative assessments, including clinical examination, laboratory tests, and radiographic imaging, will follow standard clinical practice. Additional diagnostic procedures, such as ECG, biochemical markers, Doppler ultrasound, or radiography, will be performed as clinically indicated by the operating surgeon, on-call physician, anesthesiologist, internist, or other relevant specialists, based on the patient's condition. Major adverse events include cerebrovascular events, myocardial infarction, pulmonary embolism, deep vein thrombosis, bowel ischemia, and convulsions. Minor events include nausea, vomiting, headache, and abdominal pain. Surgical complications encompass reoperation for bleeding, hematoma, wound infection, wound healing issues, implant problems (cut-out or malposition), delayed union, malunion, and avascular necrosis. General complications include pneumonia, urinary tract infection, renal insufficiency, drug allergy, and decubitus ulcers. Mortality will be recorded at 30 and 90 days postoperatively.
Patients are followed with outpatient visits at 14 days, 1 month, 2 months, 3 months. Clinical and radiographic evaluation. All complications and adverse events documented.
Data are entered into a secure, anonymized electronic database with predefined variables, units, and normal ranges.Range and consistency checks are performed to ensure data validity.All preoperative, intraoperative, and postoperative data are verified against medical records.Missing or unavailable data are documented and handled according to standard statistical practices. Standard clinical procedures are followed for patient recruitment, data collection, adverse event monitoring, and reporting.
Sample Size: A total of 120 participants (60 per group) are enrolled, sufficient to detect clinically meaningful differences in blood loss and transfusion requirements.
Statistical Analysis Data analysis will be performed using SPSS software (version 25.0; IBM, SPSS, USA). Normality of data distribution will be assessed using the Kolmogorov-Smirnov and Shapiro-Wilk tests.
Categorical (nominal) variables will be presented as counts and percentages. Continuous (quantitative) variables will be presented as mean ± standard deviation, minimum and maximum values, median, and interquartile range.Comparisons between the single-dose and two-dose tranexamic acid groups will be performed as follows: categorical variables- Chi-square test or Fisher exact test, as appropriate, continuous variables (independent samples)- Student's t-test or Mann-Whitney test, depending on data distribution, repeated measures / paired data-Student's t-test for dependent samples, Wilcoxon matched-pairs test, repeated measures ANOVA, or Friedman ANOVA, as appropriate.
Subgroup analyses will be performed according to the type of osteosynthesis (dynamic hip screw or intramedullary fixation) and dosing group for all evaluated outcomes, including incidence of allogeneic transfusion, hemoglobin drop, total and hidden blood loss, total transfused blood volume, length of hospital stay, thrombotic events, and mortality.
Statistical significance will be defined at p less than 0.05.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive a single intravenous dose of 15 mg/kg Tranexamic Acid 10-20 minutes before the surgical incision, followed by a placebo(saline solution) 3 hours later.
Drug: Tranexamic acid
Patients will receive a 15 mg/kg intravenous dose of Tranexamic acid 10-20 minutes before the surgical incision and a second intravenous dose of 15 mg/kg Tranexamic Acid 3 hours after the first dose
Drug: Tranexamic acid
15 mg/kg intravenous solution (100 mg/ml)
Incidence of allogeneic blood transfusion
Comparison of the incidence of intraoperative and postoperative allogeneic transfusions (≥1 unit of red blood cells) between patients receiving a single intravenous dose of tranexamic acid (15 mg/kg, pre-incision) and those receiving two doses (15 mg/kg pre-incision + 15 mg/kg 3 hours after the first dose).
Time frame: From start of surgery through postoperative day 5.
Hemoglobin drop
Comparison of the hemoglobin decrease between participants receiving a single dose versus those receiving two doses of tranexamic acid, measured preoperatively and on postoperative days 1, 2, and 3
Time frame: Preoperative to postoperative day 3
Total and hidden blood loss
Comparison of total and hidden blood loss between single-dose and two-dose groups.
Time frame: From start of surgery through postoperative day 3
Volume of transfused blood products
Comparison of total volume of transfused blood products (fresh frozen plasma, platelet concentrates) between groups.
Time frame: From start of surgery through postoperative day 5.
Length of hospital stay
Comparison of duration of hospitalization in days between groups.
Time frame: From surgery through hospital discharge up to 30 days postoperatively
Incidence of thrombotic events
Comparison of thrombotic events (deep vein thrombosis, pulmonary embolism, cerebrovascular event, myocardial infarction, postoperative bowel ischemia) during hospitalization and up to 90 days postoperatively.
Time frame: Up to 90 days postoperatively
Mortality
Comparison of 30-day and 90-day mortality between groups.
Time frame: 30 and 90 days postoperatively
Subgroup analysis by osteosynthesis type
Subgroup comparison according to type of osteosynthesis (DHS or intramedullary fixation) for all analyzed parameters-incidence of allogeneic transfusion, hemoglobin decrease, total and hidden blood loss, volume of transfused blood products, length of hospitalization, thrombotic events, and mortality-between participants receiving a single dose versus those receiving two doses of tranexamic acid.
Time frame: From preoperative baseline up to 90 days postoperatively
Plan to share: No
Started Feb 2026 (actual). Primary completion is estimated for May 2027, 15 months after the start.
Of 221 non-industry interventional studies with no phase under Hip Fractures, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 55. This study's planned 15 months is below that.
Counting every sponsor, half of 237 studies reached it within 29 months; a quarter within 10 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tranexamic Acid
University Hospital for Surgical Diseases St. Naum Ohridsk i- Skopje